Michael Anstey
InvestorPartner at Cambridge Innovation Capital · Partner at Start Codon
Cambridge, United Kingdom
Writes $600K – $6M checks · typically $3.3M
Find your path to Michael
607 people in our graph share verified history with Michael — schools, employers, funds. One of them is your warm intro.
Alice PillarunlockedMichael: together at University of Oxford (2004–2007)
Michael: together at Congenica
×7Michael: together at University of Oxford
Michael: together at The Boston Consulting Group
About
Michael Anstey pairs a DPhil in Zoology with co-founding an early-stage biotech targeting protein–protein interactions, backed Bicycle Therapeutics and Nuclera, and co-founded Innovate Cambridge to boost Greater Cambridge's innovation ecosystem.
Contact· self-published, not guessed
Invests in
AI & Machine LearningBiotechDeep TechHardwareHealthtechSemiconductors
Experience
- Cambridge Innovation CapitalPartnercurrent2017 — presentGreater Cambridge Area
- TRIMTECH Therapeutics LimitedBoard Membercurrent2024 — presentCambridge, England, United Kingdom
- NucleraBoard Observercurrent2024 — presentCambridge, England, United Kingdom
- ImmutrinBoard Membercurrent2022 — presentCambridge, England, United Kingdom
- EpitopeaBoard Membercurrent2021 — presentCambridge, England, United Kingdom
- Innovate CambridgeBoard Membercurrent2022 — presentCambridge, England, United Kingdom
- Start CodonBoard Membercurrent2019 — presentGreater Cambridge Area
- CongenicaBoard Member2018 — 2025Greater Cambridge Area
- STORM Therapeutics LimitedBoard Member2018 — 2023Greater Cambridge Area
- Bicycle TherapeuticsBoard Member2017 — 2020Greater Cambridge Area
- Proteorex Therapeutics Inc.Co-Founder2014 — 2018Greater Toronto Area, Canada
- The Boston Consulting GroupPrincipal2010 — 2017Toronto, Canada
- Oxford Capital PartnersInvestment Analyst2008 — 2009Greater Oxford Area
Skills & more
Valuation3Venture Capital29Leadership23Corporate Development4Due Diligence6Business Strategy30Investments9Healthcare2Strategy10Research7Management Consulting15Change Management1
+7 more
ScienceStart-upsLifesciencesPrivate EquityFinancial ModelingTeam LeadershipProject Team ManagementFrom Michael's professional profile.
Investments
Investor
ImmutrinPredictImmuneTRIMTECH Therapeutics
Per curated public sources.
Colleagues at Cambridge Innovation Capital
Adam Glinsman
Investor at Cambridge Innovation Capital
Andrew Williamson
Managing Partner at Cambridge Innovation Capital
Andy Neely
Vice Chair at Cambridge Innovation Capital
Andy Richards
Investor at Cambridge Innovation Capital
Anne Horgan
Partner at Cambridge Innovation Capital
Christopher Tapper
Senior Associate at Cambridge Innovation Capital
Damian Crowther
Entrepreneur in Residence at Cambridge Innovation Capital
Dipesh Patel
Operating Partner at Cambridge Innovation Capital
Network4
Andrew Williamson
Managing Partner at Cambridge Innovation Capital
Anne Horgan
Partner at Cambridge Innovation Capital
Christopher Tapper
Senior Associate at Cambridge Innovation Capital
Edward Inns
Principal at Cambridge Innovation Capital
Investors connected to Michael in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Michael Anstey?
- Michael Anstey pairs a DPhil in Zoology with co-founding an early-stage biotech targeting protein–protein interactions, backed Bicycle Therapeutics and Nuclera, and co-founded Innovate Cambridge to boost Greater Cambridge's innovation ecosystem.
- Where does Michael Anstey work?
- Michael Anstey is Partner at Cambridge Innovation Capital.
- What does Michael Anstey invest in?
- Michael Anstey invests in AI & Machine Learning, Biotech, Deep Tech, Hardware, Healthtech, Semiconductors.
- What check size does Michael Anstey write?
- Michael Anstey typically writes checks of $600K – $6M.
- What companies has Michael Anstey invested in?
- Investments tracked here include Immutrin, PredictImmune, TRIMTECH Therapeutics.
- Where did Michael Anstey go to school?
- Michael Anstey studied at Kauffman Fellow (Class 22); University of Oxford (DPhil, Department of Zoology); Queen's University (First Class BSc(Hons), Biology).
Same school
Also attended University of Oxford1,767
Reid HoffmanCo-founder of LinkedIn; Partner at GreylockMichael MoritzFormer Partner at Sequoia Capital; Senior Adviser at Sequoia HeritageGabriel PereyraCo-founder & President of HarveyDominic JacquessonInvestor at Index VenturesErin Price-WrightInvestor at Index VenturesJan HammerInvestor at Index Ventures
+ 1,761 more
Also attended Queen's University476
Steph TryphonasCo-founder of Collaborative RoboticsHark AhluwaliaAssociate at RevolutionSydney SloanChief Marketing Officer at Scale Venture PartnersZeya YangInvestor at IVP (Institutional Venture Partners)Curtis UrbanowiczInvestment at Makers FundSanjiv KalevarPartner at Mucker Capital
+ 470 more
Shared employers
Also worked at TRIMTECH Therapeutics Limited6
Damian Crowtherex-AstraZeneca at PICUS CAPITALJeffrey MoorePresident at MC Healthcare VenturesHakan GokerManaging Director at M VenturesGeorgia FrostSenior Associate at Dementia DiscoveryGeorgia FrostVice President at Dementia Discovery FundMarie-Claire PeakmanExecutive Director, WWBD / Partner at Pfizer Venture Investments
Also worked at Nuclera4
Also worked at Immutrin3
Also worked at STORM Therapeutics Limited7
Robert TansleyPartner at Cambridge Innovation CapitalChristine MartinHead of Ventures at University of Cambridge EnterpriseHakan GokerManaging Director at M VenturesSeiji MiyaharaSenior Investment Director at Taiho Ventures, LLCTony KouzaridesVenture Partner / Resident Knight at Fifty YearsChristopher O'DonnellPartner at Pfizer Venture Investments
+ 1 more